trial

Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

NCTId NCT00565175
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 30 (actual)
Sponsored by Jesper Ekelund
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-01
Primary completion
2011-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
famotidine

Sponsors

Jesper EkelundLead Sponsor
Finland: Lilly saatio foundationCollaborator

Investigators

1
Jesper Ekelund, MD-PhDPrincipal Investigator

Sites

5 total
Helsinki, FinlandKellokoski, FinlandLohja, FinlandVaasa, FinlandVantaa, Finland

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE4
Primary Completion Date
2011-12
Status
COMPLETED
relationships
The graph out of here
drug
famotidine
drug
lead_sponsor
Jesper Ekelund
company
collaborator
Finland: Lilly saatio foundation
company
indication
Schizophrenia
indication
Bronchiolitis Obliterans Syndrome
indication
Schizophrenia
indication
investigator
Jesper Ekelund, MD-PhD
person